Corporate Governance Report Filed: Non-compliance with Korean Best Practices Due to Singapore Incorporation, No Shareholder Return Policy


  • The company is a foreign entity incorporated in Singapore, leading to non-compliance with certain Korean corporate governance best practices (e.g., electronic voting, cumulative voting, 4-week AGM notice) due to conflicts with Singapore law.
  • The board consists of 7 members (3 inside directors, 1 non-executive, 3 outside directors), with four committees (Audit, Internal Transaction, Compensation, Outside Director Nomination) all composed of outside directors.
  • Operating loss of 67.35 billion KRW on a consolidated basis for the current period, continuing losses; no dividend or shareholder return policy established, resulting in no dividends paid.
  • Largest shareholder Mayson Partners holds 21.65%, minority 78.35%; no material M&A, divestitures, or capital changes occurred during the period.
  • No formalized CEO succession or enterprise risk management policy, but internal accounting and disclosure control regulations are in place.
  • [AI Summary]This report provides neutral information by confirming the absence of shareholder returns and some governance gaps, which are attributable to the company's Singaporean incorporation. The direct impact on stock price is likely limited, but long-term shareholder value may be influenced by future dividend policy and governance improvements.

KOSPI Filing Information


  • Filing: Corporate Governance Report Disclosure
  • Company: Prestige BioPharma (950210)
  • Submission: Prestige BioPharma Limited
  • Receipt: 06-01-2026
  • Under KRX KOSPI Market Division